In Vivo Veritas

If you had $1.9 billion and a Nobel Prize-winning platform, what would you do? If you’re CRISPR Therapeutics (CRSP), the answer seems to be: launch a drug nobody wants (yet), dilute shareholders with surgical precision, and pivot hard into in vivo editing while biotech newbies panic over cash burn. Meanwhile, the takeover rumor mill grinds […]